Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03007030 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
A Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03007030 is a Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants, below the 71-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03007030, a Phase 2 study of Malignant Mesothelioma and CD30-Positive Neoplastic Cells Present, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Brentuximab Vedotin
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03007030
The ClinicalTrials.gov registry entry for NCT03007030 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (23% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03007030 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03007030 about?
NCT03007030 is a clinical study titled "Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery". This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT03007030?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2017-04-05. Estimated completion is 2026-05-01.
What conditions does trial NCT03007030 study?
This clinical trial studies the following conditions: Malignant Mesothelioma, CD30-Positive Neoplastic Cells Present.
What interventions are being tested in trial NCT03007030?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03007030?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03007030 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
COMPLETED · Phase 2
-
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
COMPLETED · Phase 2
-
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
COMPLETED · Phase 2
-
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
COMPLETED · Phase 2
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.